In an early trial, a one-size-fits-all vaccine has shown promise in preventing the deadly pancreatic cancer from coming back. According to experts, this hard-to-treat cancer has a five-year survival rate of around 13%, and more than 80 per cent of the time, pancreatic cancer comes back.